Survival Rates of Prostate Cancer Patients after Diagnosis in Srinagarind Hospital, Khon Kaen University

Authors

  • Itsarate Sawangjaeng -
  • Supot Kamsa-ard Department of Epidemiology and Biostatistics, Faculty of Public Health, Khon Kaen University
  • Wichien Sirithanaphol Department of Surgery, Faculty of Medicine, Khon Kaen University
  • Chalongpon Santong Cancer Unit, Srinagarind hospital, Faculty of Medicine, Khon Kaen University

Keywords:

prostate cancer, survival rate, hospital-based cancer registry

Abstract

Background and objective: Prostate cancer (PC) is the most common cancer in men. Previous studies have reported survival rates of PC but haven’t updated. This study aimed to determine the survival rate of PC patients who treated at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University which is a tertiary hospital in the Northeast region of Thailand.

Methods: A retrospective cohort study was conducted. Data were retrieved from the Srinagarind hospital-based cancer registry (2013-2017) and followed up until 2019 of 672 cases. The survival rate was estimated using the Kaplan-Meier method. We reported the median survival time and the 95% confidence interval (CI). A comparison group was used to estimate the survival rate using the Log-rank test.

Result: Of 627 PC patients, a case-fatality rate of 16.0 per 100 person-years (95%CI; 14.5 - 17.7). The median survival time was 3.87 years (95%CI; 3.2 - 4.6). The respective overall survival experience rate after diagnosis at 1, 3, 5 and 7 years were 84.3 (95%CI; 81.3 - 86.9), 55.2 (95%CI; 51.2 – 59.0), 45.0 (95%CI; 41.1 - 48.9) and 37.6 (95%CI; 33.2 - 41.9) respectively. Comparing survival rate, age histological grading staging bone metastasis and surgery were different in survival between the two groups by statistically significantly. (p < 0.05)

 Conclusion: The survival rate of PC after diagnosis in Srinagarind Hospital was high. By early stage, the survival rate of patients over 7 years was 78.3%. Therefore, early detection screening is needed to improve survival rates and cured the disease.

References

International Agency for Research on Cancer (IARC). CI5XI. [Cited April 24,2022]. /Available from: https://ci5.iarc.fr/CI5-XI/Pages/age-specific-curves_sel.aspx

World Health Organization. 2020. Cancer Tomorrow. [Cited April 24,2022]. /Available from: https://gco.iarc.fr/tomorrow/en/dataviz/trends?mode=cancer&group_populations=0&multiple_populations=0&multiple_cancers=1&cancers=27

Cancer Unit, Faculty of Medicine Khon Kaen University.2018. Srinagarind Hospital, Khon Kaen University Statistical Report 2018. [Cited April 24,2022]./Available from: https://kkcr.kku.ac.th/index.php?option=com_content&view=category&id=31&Itemid=66

Hassanipour S, Delam H, Arab-Zozani M, Abdzadeh E, Ali Hosseini S, Nikbakht H. A, et al. Survival rate of prostate cancer in Asian Countries: A Systematic Review and Meta-Analysis. Ann Glob Health 2020;86:1-13

Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001–2017. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. 2020;69:1473-80.

Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011; 29: 235-241.

American Cancer Society. Survival rates for prostate cancer. (2021). [Cited April 24,2022]. /Available from: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 2016;34:1652-59.

Phanphaisarn A, Patumanond J, Settakorn J, Chaiyawat P, Klangjorhor J, Pruksakorn D. Prevalence and survival patterns of patients with bone metastasis from common cancers in Thailand. Asian Pac J Cancer Prev 2016;17:4335-40.

Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate 2014;74:210-6.

Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 2015;68:325-34.

Cui P. F, Cong X. F, Gao F, Yin J. X, Niu Z. R, Zhao S. C, et al. Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients. World J Clin Cases 2020;8:54-67.

Jeldres C, Suardi N, Perrotte P, Capitanio U, Walz J, Hutterer G. C, et al. Survival after radical prostatectomy and radiotherapy for prostate cancer : a population-based study. Can Urol Assoc J 2009;3:13-21.

Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience Eur Urol 2007;51:121-9.

Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA. Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006;106:2603-9.

Published

2022-10-19

How to Cite

1.
Sawangjaeng I, Kamsa-ard S, Sirithanaphol W, Santong C. Survival Rates of Prostate Cancer Patients after Diagnosis in Srinagarind Hospital, Khon Kaen University. SRIMEDJ [Internet]. 2022 Oct. 19 [cited 2024 Jul. 15];37(5):458-66. Available from: https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/254625

Issue

Section

Original Articles